Nuvation Bio Q2 revenue rises to $31.7 million; net loss widens to $62.8 million
Nuvation Bio reported second quarter 2026 results, with total revenue of $31.7 million, up from $4.8 million a year earlier, driven by $23.2 million in net product revenue from IBTROZI. The net loss widened to $62.8 million, or $(0.18) per share, from $59.0 million, or $(0.17) per share, a year earlier, so shareholders face higher losses even as revenue grew.
Key points
- Total revenue was $31.7 million for the quarter ended June 30, 2026, versus $4.8 million a year earlier; net product revenue from IBTROZI was $23.2 million.
- Net loss was $62.8 million, or $(0.18) per share, compared with $59.0 million, or $(0.17) per share, in the second quarter of 2025.
- Cash, cash equivalents, and marketable securities were $661.0 million as of June 30, 2026, before $36.5 million in net overallotment proceeds received in July 2026.
- The company completed a public offering of 0.75% Convertible Senior Notes in July 2026 with estimated net proceeds of approximately $279.1 million.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.